WEBULL
News
TENX
12.82
+8.74%
1.03
Roth MKM Reaffirms Their Buy Rating on Tenax Therapeutics (TENX)
TipRanks · 16h ago
Optimistic Outlook on Tenax Therapeutics: Buy Rating Backed by Promising Clinical Developments
TipRanks · 1d ago
Tenax Therapeutics Advances Phase 3 Study on Levosimendan for PH-HFpEF
TipRanks · 1d ago
Tenax Therapeutics Advances LEVEL Phase 3 Study With Enrollment Completion Expected in 2026
Reuters · 1d ago
Tenax Therapeutics reports result of prespecified blinded sample size assessment
TipRanks · 1d ago
Tenax Therapeutics Announces Prespecified Blinded Sample Size Re-Estimation Of LEVEL Demonstrated Trial Is Powered At Well Over 90% To Detect 25 Meter Change In 6MWD, Primary Endpoint
Benzinga · 1d ago
TENAX THERAPEUTICS INC - LEVEL TRIAL ON TRACK TO COMPLETE ENROLLMENT IN FIRST HALF OF 2026; TOPLINE DATA EXPECTED IN SECOND HALF OF 2026
Reuters · 1d ago
Tenax Therapeutics Price Target Raised to $25.00/Share From $14.00 by Guggenheim
Dow Jones · 1d ago
Tenax Therapeutics Is Maintained at Buy by Guggenheim
Dow Jones · 1d ago
Guggenheim Maintains Buy on Tenax Therapeutics, Raises Price Target to $25
Benzinga · 1d ago
Tenax Therapeutics price target raised to $25 from $14 at Guggenheim
TipRanks · 1d ago
Tenax Therapeutics Announces Result of Prespecifed Blinded Sample Size Assessment
Barchart · 1d ago
Weekly Report: what happened at TENX last week (1208-1212)?
Weekly Report · 3d ago
Tenax Therapeutics CMO Makes Bold Stock Purchase!
TipRanks · 12/11 02:01
Tenax Therapeutics Chief Medical Officer Stuart Rich Reports Acquisition of Common Shares
Reuters · 12/10 23:49
Weekly Report: what happened at TENX last week (1201-1205)?
Weekly Report · 12/08 10:08
Tenax Therapeutics Chief Medical Officer Stuart Rich Reports Acquisition of Common Shares
Reuters · 12/05 22:46
Weekly Report: what happened at TENX last week (1124-1128)?
Weekly Report · 12/01 10:04
Tenax Therapeutics Executives to Present at Major Healthcare Investor Conferences
Reuters · 11/25 12:00
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga · 11/24 21:05
More
Webull provides a variety of real-time TENX stock news. You can receive the latest news about Tenax Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About TENX
Tenax Therapeutics, Inc. is a Phase 3 development-stage pharmaceutical company. The Company is focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The Company's products include TNX-201 (oral enteric-coated imatinib) and TNX-103 (oral levosimendan). The Company is developing dosing and a formulation of imatinib mesylate, a kinase inhibitor for the treatment of pulmonary arterial hypertension (PAH). The Company’s other programs include TNX-101 and TNX-102. Levosimendan is a calcium sensitizer/K-ATP activator developed for intravenous use in hospitalized patients with acutely decompensated heart failure. The Company has completed the Phase II trial of levosimendan in patients with PH and heart failure with preserved ejection fraction (HFpEF).